Global Health Innovation Act of 2017

Bill: 115-hr-1660
Sponsor: full_name: Rep. Sires, Albio [D-NJ-8]
Introduced: 2017-03-21
Policy area: International Affairs
Subjects: Child health

Congressional oversight

Drug therapy

Foreign aid and international relief

HIV/AIDS

Health programs administration and funding

Health promotion and preventive care

Health technology, devices, supplies

Immunology and vaccination

Infectious and parasitic diseases

Medical tests and diagnostic methods

Product development and innovation

Public-private cooperation

U.S. Agency for International Development (USAID)

Women's health

World health
Latest action: action_date: 2019-01-03
text: Became Public Law No: 115-411.

Summaries:
action_date: 2017-03-21
action_desc: Introduced in House
text: <p><strong>Global Health Innovation Act of 2017</strong></p> <p>This bill directs the Administrator of the U.S. Agency for International Development (USAID) to report to Congress, annually for four years, on the development and use of global health innovations in USAID programs, projects, and activities.</p>

action_date: 2018-01-18
action_desc: Passed House without amendment
text: <p>(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)</p> <p><strong>Global Health Innovation Act of 2017</strong></p> <p> (Sec. 2) This bill directs the Administrator of the U.S. Agency for International Development (USAID) to report to Congress, annually for four years, on the development and use of global health innovations in USAID programs, projects, and activities.</p> <p> Such reports shall include descriptions of: (1) goals and progress towards their achievement; (2) how innovation has advanced USAID's commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases; (3) how USAID, alone and in partnerships, is leveraging U.S. investments to achieve greater health innovation; and (4) coordination with other federal departments.</p>

action_date: 2018-03-22
action_desc: Reported to Senate without amendment
text: <p><strong>Global Health Innovation Act of 2017</strong></p> <p> (Sec. 2) This bill directs the Administrator of the U.S. Agency for International Development (USAID) to report to Congress, annually for four years, on the development and use of global health innovations in USAID programs, projects, and activities.</p> <p> Such reports shall include descriptions of: (1) goals and progress towards their achievement; (2) how innovation has advanced USAID's commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases; (3) how USAID, alone and in partnerships, is leveraging U.S. investments to achieve greater health innovation; and (4) coordination with other federal departments.</p>

action_date: 2019-01-03
action_desc: Public Law
text: <p><strong>Global Health Innovation Act of 2017</strong></p> <p> This bill directs the U.S. Agency for International Development (USAID) to report to Congress, annually for four years, on the development and use of global health innovations in USAID programs, projects, and activities.</p> <p> Such reports shall include topics including: (1) USAID's health product development goals and progress towards their achievement; (2) how innovation has advanced USAID's commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases; (3) how USAID, alone and in partnerships, is leveraging U.S. investments to achieve greater health innovation; and (4) coordination with other federal departments.</p>

tv_txt: I 115th CONGRESS 1st Session H. R. 1660 IN THE HOUSE OF REPRESENTATIVES March 21, 2017 Mr. Sires (for himself, Mr. Diaz-Balart , Mr. Connolly , Mr. Engel , Mr. Sherman , Mr. Cicilline , Mr. Keating , Ms. Ros-Lehtinen , Mr. Donovan , and Mr. Smith of New Jersey ) introduced the following bill; which was referred to the Committee on Foreign Affairs A BILL To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1. Short title This Act may be cited as the Global Health Innovation Act of 2017 . 2. Annual report (a) In general Not later than 180 days after the date of the enactment of this Act, and annually thereafter for a period of 4 years, the Administrator of the United States Agency for International Development shall submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency. (b) Matters To Be Included The report required by subsection (a) shall include the following: (1) A description of— (A) the extent to which global health innovations described in subsection (a) include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations; (B) how innovation has advanced the Agency’s commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases, as well as furthered by the Global Health Strategic Framework; (C) how goals are set for health product development in relation to the Agency’s health-related goals and how progress and impact are measured towards those goals; (D) how the Agency’s investments in innovation relate to its stated goals; and (E) progress made towards health product development goals. (2) How the Agency, both independently and with partners, donors, and public-private partnerships, is— (A) leveraging United States investments to achieve greater impact in health innovation; (B) engaging in activities to develop, advance, and introduce affordable, available, and appropriate global health products; and (C) scaling up appropriate health innovations in the development pipeline. (3) A description of collaboration and coordination with other Federal departments and agencies, including the Centers for Disease Control and Prevention, in support of global health product development, including a description of how the Agency is working to ensure critical gaps in product development for global health are being filled. (4) A description of how the Agency is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.

tv_txt: I 115th CONGRESS 2d Session H. R. 1660 IN THE HOUSE OF REPRESENTATIVES AN ACT To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1. Short title This Act may be cited as the Global Health Innovation Act of 2017 . 2. Annual report (a) In general Not later than 180 days after the date of the enactment of this Act, and annually thereafter for a period of 4 years, the Administrator of the United States Agency for International Development shall submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency. (b) Matters To Be Included The report required by subsection (a) shall include the following: (1) A description of— (A) the extent to which global health innovations described in subsection (a) include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations; (B) how innovation has advanced the Agency’s commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases, as well as furthered by the Global Health Strategic Framework; (C) how goals are set for health product development in relation to the Agency’s health-related goals and how progress and impact are measured towards those goals; (D) how the Agency’s investments in innovation relate to its stated goals; and (E) progress made towards health product development goals. (2) How the Agency, both independently and with partners, donors, and public-private partnerships, is— (A) leveraging United States investments to achieve greater impact in health innovation; (B) engaging in activities to develop, advance, and introduce affordable, available, and appropriate global health products; and (C) scaling up appropriate health innovations in the development pipeline. (3) A description of collaboration and coordination with other Federal departments and agencies, including the Centers for Disease Control and Prevention, in support of global health product development, including a description of how the Agency is working to ensure critical gaps in product development for global health are being filled. (4) A description of how the Agency is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.

Passed the House of Representatives January 18, 2018. Karen L. Haas, Clerk.

tv_txt: IIB 115th CONGRESS 2d Session H. R. 1660 IN THE SENATE OF THE UNITED STATES January 19, 2018 Received; read twice and referred to the Committee on Foreign Relations AN ACT To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1. Short title This Act may be cited as the Global Health Innovation Act of 2017 . 2. Annual report (a) In general Not later than 180 days after the date of the enactment of this Act, and annually thereafter for a period of 4 years, the Administrator of the United States Agency for International Development shall submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency. (b) Matters To Be Included The report required by subsection (a) shall include the following: (1) A description of— (A) the extent to which global health innovations described in subsection (a) include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations; (B) how innovation has advanced the Agency’s commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases, as well as furthered by the Global Health Strategic Framework; (C) how goals are set for health product development in relation to the Agency’s health-related goals and how progress and impact are measured towards those goals; (D) how the Agency’s investments in innovation relate to its stated goals; and (E) progress made towards health product development goals. (2) How the Agency, both independently and with partners, donors, and public-private partnerships, is— (A) leveraging United States investments to achieve greater impact in health innovation; (B) engaging in activities to develop, advance, and introduce affordable, available, and appropriate global health products; and (C) scaling up appropriate health innovations in the development pipeline. (3) A description of collaboration and coordination with other Federal departments and agencies, including the Centers for Disease Control and Prevention, in support of global health product development, including a description of how the Agency is working to ensure critical gaps in product development for global health are being filled. (4) A description of how the Agency is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.

Passed the House of Representatives January 18, 2018. Karen L. Haas, Clerk

tv_txt: II Calendar No. 364 115th CONGRESS 2d Session H. R. 1660 IN THE SENATE OF THE UNITED STATES January 19, 2018 Received; read twice and referred to the Committee on Foreign Relations March 22, 2018 Reported by Mr. Corker , without amendment AN ACT To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1. Short title This Act may be cited as the Global Health Innovation Act of 2017 . 2. Annual report (a) In general Not later than 180 days after the date of the enactment of this Act, and annually thereafter for a period of 4 years, the Administrator of the United States Agency for International Development shall submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency. (b) Matters To Be Included The report required by subsection (a) shall include the following: (1) A description of— (A) the extent to which global health innovations described in subsection (a) include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations; (B) how innovation has advanced the Agency’s commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases, as well as furthered by the Global Health Strategic Framework; (C) how goals are set for health product development in relation to the Agency’s health-related goals and how progress and impact are measured towards those goals; (D) how the Agency’s investments in innovation relate to its stated goals; and (E) progress made towards health product development goals. (2) How the Agency, both independently and with partners, donors, and public-private partnerships, is— (A) leveraging United States investments to achieve greater impact in health innovation; (B) engaging in activities to develop, advance, and introduce affordable, available, and appropriate global health products; and (C) scaling up appropriate health innovations in the development pipeline. (3) A description of collaboration and coordination with other Federal departments and agencies, including the Centers for Disease Control and Prevention, in support of global health product development, including a description of how the Agency is working to ensure critical gaps in product development for global health are being filled. (4) A description of how the Agency is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.

March 22, 2018 Reported without amendment

tv_txt: I One Hundred Fifteenth Congress of the United States of America At the Second Session Begun and held at the City of Washington on Wednesday, the third day of January, two thousand and eighteen H. R. 1660 AN ACT To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1. Short title This Act may be cited as the Global Health Innovation Act of 2017 . 2. Annual report (a) In general Not later than 180 days after the date of the enactment of this Act, and annually thereafter for a period of 4 years, the Administrator of the United States Agency for International Development shall submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency. (b) Matters To Be Included The report required by subsection (a) shall include the following: (1) A description of— (A) the extent to which global health innovations described in subsection (a) include drugs, diagnostics, devices, vaccines, electronic and mobile health technologies, and related behavior change and service delivery innovations; (B) how innovation has advanced the Agency’s commitments to achieving an HIV/AIDS-free generation, ending preventable child and maternal deaths, and protecting communities from infectious diseases, as well as furthered by the Global Health Strategic Framework; (C) how goals are set for health product development in relation to the Agency’s health-related goals and how progress and impact are measured towards those goals; (D) how the Agency’s investments in innovation relate to its stated goals; and (E) progress made towards health product development goals. (2) How the Agency, both independently and with partners, donors, and public-private partnerships, is— (A) leveraging United States investments to achieve greater impact in health innovation; (B) engaging in activities to develop, advance, and introduce affordable, available, and appropriate global health products; and (C) scaling up appropriate health innovations in the development pipeline. (3) A description of collaboration and coordination with other Federal departments and agencies, including the Centers for Disease Control and Prevention, in support of global health product development, including a description of how the Agency is working to ensure critical gaps in product development for global health are being filled. (4) A description of how the Agency is coordinating and aligning global health innovation activities between the Global Development Lab, the Center for Accelerating Innovation and Impact, and the Bureau for Global Health.

Speaker of the House of Representatives. Vice President of the United States and President of the Senate.